We are live on
!
Find out more
SCM
Sio Capital Management Portfolio holdings
AUM
$604M
1-Year Est. Return
96.57%
This Fund
S&P 500
This Quarter
Est. Return
+0.02%
1 Year Est. Return
+96.57%
3 Year Est. Return
+564.25%
5 Year Est. Return
+486.18%
10 Year Est. Return
+2,856.71%
AUM
$697M
AUM Growth
+$61.6M
(+9.7%)
Cap. Flow
+$121M
Cap. Flow
% of AUM
17.37%
Top 10 Holdings %
Top 10 Hldgs %
45.13%
Holding
90
New
22
Increased
24
Reduced
17
Closed
14
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cencora
COR
|
+$29.7M |
| 2 |
WAY
Waystar Holding Corp
WAY
|
+$27.3M |
| 3 |
Corcept Therapeutics
CORT
|
+$25.2M |
| 4 |
Icon
ICLR
|
+$24.5M |
| 5 |
Maximus
MMS
|
+$21.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cigna
CI
|
+$47.4M |
| 2 |
Sanofi
SNY
|
+$34.1M |
| 3 |
Celcuity
CELC
|
+$30.9M |
| 4 |
Zimmer Biomet
ZBH
|
+$29.6M |
| 5 |
Kenvue
KVUE
|
+$25.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.44% |
| 2 | Industrials | 7.07% |
| 3 | Miscellaneous | 0.49% |
| 4 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Simulations Plus
SLP
$372M
| $2.36K | ﹤0.01% |
+200
| New | +$2.95K |
|
77
Alkermes
ALKS
$7.95B
| – | – |
-95,353
| Closed | -$2.67M |
|
78
Avalo Therapeutics
AVTX
$1.05B
| – | – |
-72,173
| Closed | -$1.31M |
|
|
79
Cigna
CI
$73.7B
| – | – |
-172,203
| Closed | -$47.4M |
|
80
Centene
CNC
$32B
| – | – |
-274,350
| Closed | -$11.2M |
|
81
Charles River Laboratories
CRL
$13.9B
| – | – |
-54,985
| Closed | -$11M |
|
82
Fulcrum Therapeutics
FULC
$294M
| – | – |
-382,000
| Closed | -$4.32M |
|
83
IDEAYA Biosciences
IDYA
$3.87B
| – | – |
-75,730
| Closed | -$2.62M |
|
|
84
Kenvue
KVUE
$36.8B
| – | – |
-1,465,442
| Closed | -$25.3M |
|
85
McKesson
MCK
$104B
| – | – |
-6,400
| Closed | -$5.25M |
|
86
NextCure
NXTC
$27.9M
| – | – |
-10,940
| Closed | -$155K |
|
87
PUT
Outlook Therapeutics
OTLK
$156M
| – | – |
-1,125,400
| Closed | -$1.78M |
|
88
PUT
Rhythm Pharmaceuticals
RYTM
$7.38B
| – | – |
-265,700
| Closed | -$28.4M |
|
|
VTYX
89
DELISTED
Ventyx Biosciences
VTYX
| – | – |
-387,751
| Closed | -$3.5M |
|
90
BrightSpring Health Services
BTSG
$11.7B
| – | – |
-308,010
| Closed | -$11.5M |
|
Similar funds
EFL
V
MAM
RCM
AMG
VV
VCP
EHI
Sio Capital Management's Q1 2026 Portfolio in Review
As of Q1 2026, Sio Capital Management held 90 positions worth $697M, up 9.7% from $636M the previous quarter. Its ten largest holdings account for 45% of the portfolio.
Sio Capital Management deployed $121M of net new capital in Q1 2026, opening 22 new positions and adding to 24 existing holdings. Its largest new stake was Corcept Therapeutics: 674,759 shares worth $27.2M.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 84% a quarter earlier, followed by Industrials and Miscellaneous.
On the sell side, the largest reduction was Sanofi, an estimated $34.1M trimmed.
- Sio Capital Management's largest Q1 2026 buy was Corcept Therapeutics: 674,759 shares worth $27.2M.
- Sio Capital Management added most to Cencora in Q1 2026, an estimated $29.7M increase.
- Sio Capital Management's biggest Q1 2026 reduction was Sanofi, cutting an estimated $34.1M.
- Sio Capital Management fully exited Cigna in Q1 2026, selling an estimated $47.4M.
- Sio Capital Management's ten largest holdings make up 45% of its $697M portfolio in Q1 2026.
- Sio Capital Management opened 22 new positions and closed 14 in Q1 2026.
- Sio Capital Management's portfolio value rose 9.7% quarter-over-quarter to $697M.
Based on Sio Capital Management's 13F filing for Q1 2026, filed 14 May 2026.